Breakingviews TV: Drug dreams

Moderna’s hoped-for $8 bln IPO valuation is a rich antidote to the funk hitting tech stocks. Rob Cyran explains that although the biotech firm’s technology is promising, it has no drugs near commercial readiness. That’s all the more reason to grab the money while it can.

from Reuters Video: Breakingviews https://ift.tt/2PchlUc